A landmark step against one of India’s fastest-growing diseases
India has approved QDENGA, the country’s first dengue vaccine, for individuals aged 4 to 60 years, marking a significant breakthrough in the fight against one of the nation’s most persistent mosquito-borne diseases. Approved by the Drug Controller General of India (DCGI), Takeda Biopharmaceuticals India’s vaccine introduces a new approach to dengue prevention by eliminating the need for pre-vaccination screening. The decision is expected to reshape India’s dengue-control strategy, particularly as the country continues to record a high and often underreported disease burden.
Why dengue vaccination remained a challenge
Dengue, caused by four closely related virus serotypes (DENV-1 to DENV-4), has become endemic across much of India, especially in densely populated urban and peri-urban regions. While official figures recorded over 113,000 cases in 2025, scientific estimates suggest the actual number of infections runs into tens of millions annually because many cases remain undiagnosed or unreported.
Developing an effective vaccine has been difficult due to antibody-dependent enhancement (ADE), where incomplete immunity may increase the risk of severe disease following a later infection. Earlier vaccines, particularly Dengvaxia, required confirmation of previous dengue infection before administration, making large-scale immunisation expensive and operationally complex.
What makes QDENGA different
QDENGA is India’s first licensed dengue vaccine that can be administered irrespective of an individual’s previous dengue exposure. The absence of mandatory pre-vaccination testing significantly simplifies programme implementation and reduces logistical costs.
The vaccine is approved for people between 4 and 60 years of age and follows a two-dose schedule, with injections administered three months apart. Regulatory approval is backed by an extensive global clinical programme involving over 28,000 participants across 19 Phase I, II and III trials conducted in both endemic and non-endemic regions.
Broad protection backed by long-term evidence
QDENGA is a live-attenuated tetravalent vaccine engineered to protect against all four dengue virus serotypes. Built on a DENV-2 backbone with components from the other three serotypes, it aims to generate balanced immune responses across the virus spectrum.
Long-term Phase III TIDES trial data showed an efficacy of 61.2% in preventing virologically confirmed dengue over 4.5 years. A booster dose increased efficacy to 74.3%, while protection against dengue-related hospitalisation reached 90.6%. Studies have also demonstrated sustained protection for up to seven years without identifying new major safety concerns.
Global acceptance and India's manufacturing advantage
The World Health Organization recommends QDENGA for use in dengue-endemic regions without pre-vaccination screening. Since its global rollout in 2022, the vaccine has secured approvals in 43 countries, with over 32 million doses distributed worldwide.
To support future demand, Takeda has partnered with Indian vaccine manufacturer Biological E, which is expected to produce 50 million doses annually. Domestic manufacturing could lower costs, strengthen supply chains and position India as a major supplier of dengue vaccines across South Asia.
Given the broad eligible age group, policymakers are likely to prioritise schoolchildren, high-risk urban populations and vulnerable communities before considering wider coverage.
A Turning Point in India’s Fight Against Dengue
The approval of QDENGA represents more than the launch of a new vaccine; it marks a strategic evolution in India's public health response to dengue. By removing the barrier of pre-vaccination screening and offering broad protection against all four virus serotypes, the vaccine creates opportunities for scalable immunisation in high-burden regions. Its success, however, will depend on affordable access, strong surveillance, transparent risk communication and continued mosquito-control efforts. If effectively integrated into existing public health programmes, QDENGA could significantly reduce severe disease, ease pressure on healthcare systems and redefine India's long-term strategy against dengue.
(With agency inputs)
